MCL

14 registered clinical trials studyying MCL — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Pati NCT07257055	M.D. Anderson Cancer Center	Phase 2
Not Yet Recruiting	Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human NCT07259070	Institute of Hematology & Blood Diseases Hospital, China	Phase 1 / Phase 2
Recruiting	Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT07460362	Peking University Third Hospital	Phase 2
Recruiting	Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients NCT06463691	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636	Essen Biotech	Phase 1 / Phase 2
Enrolling By Invitation	Real-world Study of Acalabrutinib NCT06767891	Ruijin Hospital	—
Active Not Recruiting	A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma NCT06192888	Memorial Sloan Kettering Cancer Center	Phase 1
Terminated	A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma NCT05788289	Memorial Sloan Kettering Cancer Center	Phase 2
Unknown	Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy NCT05414162	University Hospital, Bonn	—
Withdrawn	HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691	Hutchmed	Phase 1
Active Not Recruiting	Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma NCT05214183	Nordic Lymphoma Group	Phase 2
Terminated	Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy NCT04806035	TG Therapeutics, Inc.	Phase 1
Active Not Recruiting	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma NCT03625037	Genmab	Phase 1 / Phase 2
Terminated	Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle NCT02488512	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Phase 2